Biotech | August 11, 2021
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Company working on COVID vaccine INO 4800
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
